Home/Cervical Cancer Awareness Month

Cervical Cancer Awareness Month

Cervical Cancer Awareness Month, observed every January, is designed to raise awareness of cervical cancer and to promote education, prevention, early detection, and treatment of this potentially life-threatening disease. Cervical Cancer Awareness Month seeks to promote routine screenings and early detection through Pap smears and HPV testing; to encourage individuals, particularly adolescents, to get vaccinated against HVP to reduce the risk of developing cervical cancer; to educate individuals about the risk factors for and early symptoms of the disease; to reduce the stigma and fear associated with cervical cancer; to advocate for access to healthcare services, particularly in underserved communities; and to provide support, resources, and a sense of community for those affected, including patients, families, and caregivers. To aid in promoting and raising awareness of cervical cancers, the International Journal of Gynecological Cancer is pleased to offer free access to a selection of research articles and reviews from the past year. Cibula D, Raspollini MR, Planchamp F, et al. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*. International Journal of Gynecological Cancer 2023;33:649-666 Parpinel G, Laas-Faron E, Balaya V, et al. Survival after sentinel lymph node biopsy for early cervical cancers: a systematic review and meta-analysis. International Journal of Gynecological Cancer 2023;33:1853-1860 Xia L, Wang J, Wang C, et al. Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study. International Journal of Gynecological Cancer 2023;33:1861-1868 Salcedo MP, Lathrop E, Osman N, et al. The Mulher Study: cervical cancer screening with primary HPV testing in Mozambique. International Journal of Gynecological Cancer 2023;33:1869-1874 Nitecki R, Ramirez PT, Dundr P, et al. MILACC study: could undetected lymph node micrometastases have impacted recurrence rate in the LACC trial? International Journal of Gynecological Cancer 2023;33:1684-1689 Frumovitz M, Morani AC, Aziz A, et al. PET/CT scan improves detection of metastatic disease compared with CT scan alone in women with high-grade neuroendocrine cervical cancer: a NeCTuR study. International Journal of Gynecological Cancer 2023;33:1690-1694 Michaan N, Wenkert A, Even-Sapir E, et al. Prognostic significance of delayed complete metabolic response on PET/CT after primary chemoradiation treatment of cervical cancer. International Journal of Gynecological Cancer 2023;33:1695-1701 Nakisige C, de Fouw M, Kabukye J, et al. Artificial intelligence and visual inspection in cervical cancer screening. International Journal of Gynecological Cancer 2023;33:1515-1521 Bizzarri N, Russo L, Dolciami M, et al. Radiomics systematic review in cervical cancer: gynecological oncologists’ perspective. International Journal of Gynecological Cancer 2023;33:1522-1541 Phoolcharoen N, Areeruk W, Kantathavorn N, et al. Self- and physician-collected high-risk human papillomavirus (HPV) testing to detect high-grade cervical lesions among Thai women. International Journal of Gynecological Cancer 2023;33:1354-1358 Salvo G, Flores Legarreta A, Ramalingam P, et al. Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study. International Journal of Gynecological Cancer 2023;33:1359-1369 Mauro J, Viveros-Carreño D, Vizzielli G, et al. Survival after sentinel node biopsy alone in early-stage cervical cancer: a systematic review. International Journal of Gynecological Cancer 2023;33:1370-1375 Viveros-Carreño D, Vieira-Serna S, Grillo-Ardila CF, et al. Definitive pelvic radiotherapy for patients with newly diagnosed stage IVB cervical cancer: a systematic review. International Journal of Gynecological Cancer 2023;33:1057-1062 Chargari C, Tanderup K, Planchamp F, et al. ESGO/ESTRO quality indicators for radiation therapy of cervical cancer. International Journal of Gynecological Cancer 2023;33:862-875 Snyman LC, Richter KL, Lukhwareni A, et al. Cytology compared with Hybrid Capture 2 human papilloma virus cervical cancer screening in HIV positive and HIV negative South African women. International Journal of Gynecological Cancer 2023;33:669-675 Ishikawa M, Shibata T, Kataoka T on behalf of the Gynecologic Cancer Study Group in Japan Clinical Oncology Group, et al. Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311). International Journal of Gynecological Cancer 2023;33:692-700 Carneiro VCG, Batista TP, Andrade MR, et al. Proof-of-concept randomized phase II non-inferiority trial of simple versus type B2 hysterectomy in early-stage cervical cancer ≤2 cm (LESSER). International Journal of Gynecological Cancer 2023;33:498-503 Gomez Cherey JF, Payalef SN, Fleider L, et al. Microbiota unbalance in relation to high-risk human papillomavirus cervical infection. International Journal of Gynecological Cancer 2023;33:482-488 Bizzarri N, Chiantera V, Loverro M, et al. Minimally invasive versus open pelvic exenteration in gynecological malignancies: a propensity-matched survival analysis. International Journal of Gynecological Cancer 2023;33:190-197 Suzuki Y, Huang Y, Ferris J, et al. Prescription of hormone replacement therapy among cervical cancer patients with treatment-induced premature menopause. International Journal of Gynecological Cancer 2023;33:26-34